BioCentury | Dec 2, 2016
Company News

Portage spins out EyGen

...preclinical opthalmologic and inflammatory compounds through proof of concept. The newco's lead compound is Portage’s PPL-003...
...a pre-IND meeting in mid-2017. Portage Biotech Inc. (OTCBB:PTGEF; CNSX:PBT.U), Toronto, Ontario Business: Opthalmic, Inflammatory Nora Weintraub PPL-003 Portage...
BioCentury | Apr 15, 2013
Company News

PPL other research news

...PTH.L's PPL Therapeutics Inc. subsidiary (Blacksburg, Va.) said it has produced salmon calcitonin in the milk...
...then purified in a one-step process and released from its fusion partner using enzyme cleavage. PPL Therapeutics plc...
BioCentury | Apr 15, 2013
Company News

PPL, Roslin Institute other research news

...plasma protein gene and the marker gene, while 2 others carry only the reporter gene. PPL...
...proof-of-principle for the technology. The researchers plan to publish the work in a scientific journal. PPL Therapeutics plc...
BioCentury | Dec 3, 2012
Clinical News

Latanoprost punctal plug delivery system: Phase II data

...glaucoma or ocular hypertension regardless of plug loss (n=57) in the open-label, U.S. Phase II PPL...
BioCentury | Dec 3, 2012
Clinical News

Latanoprost punctal plug delivery system: Phase II data

...glaucoma or ocular hypertension regardless of plug loss (n=77) in the open-label, U.S. Phase II PPL...
BioCentury | Mar 28, 2011
Company News

Ambrilia, TaiMed deal

...front and is eligible for up to $7.6 million in milestones. The PI program includes PPL-100...
BioCentury | Jun 15, 2009
Company News

Ambrilia, Merck infectious news

...a pair of deals in 2003 and 2006 covering the program that includes lead compound PPL-100...
BioCentury | Jan 12, 2009
Company News

Ambrilia, Merck infectious news

...seeking are undisclosed. Merck declined to comment. Merck put development of the program's lead compound, PPL-100...
BioCentury | Aug 4, 2008
Analyst Picks & Changes

Analysts picks & changes

...down after partner Merck (NYSE:MRK) put a development hold on MK-8122, a phosphorylated prodrug of PPL-100...
...BX). But since Merck did not return rights, he thinks there is a chance the PPL-100...
BioCentury | Aug 4, 2008
Clinical News

MK-8122: Phase I hold

...Inc. (TSX:AMB), Verdun, Quebec Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-8122 (formerly PPL-100...
Items per page:
1 - 10 of 210
BioCentury | Dec 2, 2016
Company News

Portage spins out EyGen

...preclinical opthalmologic and inflammatory compounds through proof of concept. The newco's lead compound is Portage’s PPL-003...
...a pre-IND meeting in mid-2017. Portage Biotech Inc. (OTCBB:PTGEF; CNSX:PBT.U), Toronto, Ontario Business: Opthalmic, Inflammatory Nora Weintraub PPL-003 Portage...
BioCentury | Apr 15, 2013
Company News

PPL other research news

...PTH.L's PPL Therapeutics Inc. subsidiary (Blacksburg, Va.) said it has produced salmon calcitonin in the milk...
...then purified in a one-step process and released from its fusion partner using enzyme cleavage. PPL Therapeutics plc...
BioCentury | Apr 15, 2013
Company News

PPL, Roslin Institute other research news

...plasma protein gene and the marker gene, while 2 others carry only the reporter gene. PPL...
...proof-of-principle for the technology. The researchers plan to publish the work in a scientific journal. PPL Therapeutics plc...
BioCentury | Dec 3, 2012
Clinical News

Latanoprost punctal plug delivery system: Phase II data

...glaucoma or ocular hypertension regardless of plug loss (n=57) in the open-label, U.S. Phase II PPL...
BioCentury | Dec 3, 2012
Clinical News

Latanoprost punctal plug delivery system: Phase II data

...glaucoma or ocular hypertension regardless of plug loss (n=77) in the open-label, U.S. Phase II PPL...
BioCentury | Mar 28, 2011
Company News

Ambrilia, TaiMed deal

...front and is eligible for up to $7.6 million in milestones. The PI program includes PPL-100...
BioCentury | Jun 15, 2009
Company News

Ambrilia, Merck infectious news

...a pair of deals in 2003 and 2006 covering the program that includes lead compound PPL-100...
BioCentury | Jan 12, 2009
Company News

Ambrilia, Merck infectious news

...seeking are undisclosed. Merck declined to comment. Merck put development of the program's lead compound, PPL-100...
BioCentury | Aug 4, 2008
Analyst Picks & Changes

Analysts picks & changes

...down after partner Merck (NYSE:MRK) put a development hold on MK-8122, a phosphorylated prodrug of PPL-100...
...BX). But since Merck did not return rights, he thinks there is a chance the PPL-100...
BioCentury | Aug 4, 2008
Clinical News

MK-8122: Phase I hold

...Inc. (TSX:AMB), Verdun, Quebec Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-8122 (formerly PPL-100...
Items per page:
1 - 10 of 210